MTVA
MetaVia Inc.

14,808
Mkt Cap
$5.01M
Volume
4,308.00
52W High
$23.10
52W Low
$1.43
PE Ratio
-0.10
MTVA Fundamentals
Price
$1.51
Prev Close
$1.59
Open
$1.55
50D MA
$4.66
Beta
1.00
Avg. Volume
285,676.60
EPS (Annual)
-$39.13
P/B
0.53
Rev/Employee
$0.00
$0.134
Loading...
Loading...
News
all
press releases
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR...
PR Newswire·13d ago
News Placeholder
More News
News Placeholder
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 MetaVia Builds Comprehensive Global Patent Protection...
PR Newswire·17d ago
News Placeholder
What Does the Market Think About MetaVia Inc?
read more...
Benzinga·1mo ago
News Placeholder
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering...
PR Newswire·1mo ago
News Placeholder
MetaVia Stock Slides After Pricing Public Offering
(RTTNews) - MetaVia Inc. (MTVA) shares traded at $3.4050, down 39.03% or $2.18 lower, after the company announced the pricing of an $8.1 million underwritten public offering...
Nasdaq News: Markets·2mo ago
News Placeholder
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering PR Newswire CAMBRIDGE, Mass., Jan. 15, 2026...
PR Newswire·2mo ago
News Placeholder
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic...
PR Newswire·2mo ago
News Placeholder
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference PR Newswire CAMBRIDGE, Mass., Dec. 29...
PR Newswire·2mo ago
News Placeholder
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire CAMBRIDGE, Mass., Dec. 22, 2025 CAMBRIDGE, Mass...
PR Newswire·2mo ago
News Placeholder
IMG, MTVA, USREF, TGL: These Four Stocks Trade Ex-Reverse Split On Friday
A reverse split raises the stock’s price by reducing the share count, helping the company regain compliance and avoid delisting.
Stocktwits·3mo ago
<
1
2
...
>

Latest MTVA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.